Venturi Wealth Management LLC Buys New Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Venturi Wealth Management LLC bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 12,067 shares of the company’s stock, valued at approximately $143,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Gladius Capital Management LP bought a new stake in Roivant Sciences in the 3rd quarter valued at about $35,000. US Bancorp DE increased its holdings in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares in the last quarter. GAMMA Investing LLC increased its holdings in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares in the last quarter. Quarry LP increased its holdings in Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock worth $91,000 after purchasing an additional 6,667 shares in the last quarter. 64.76% of the stock is owned by institutional investors.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now directly owns 163,264 shares of the company’s stock, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CIO Mayukh Sukhatme sold 185,946 shares of the stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $12.00, for a total value of $2,231,352.00. Following the transaction, the executive now directly owns 18,836,547 shares of the company’s stock, valued at approximately $226,038,564. This trade represents a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,288,170 shares of company stock valued at $26,547,299. Company insiders own 7.90% of the company’s stock.

Roivant Sciences Trading Down 0.4 %

Shares of ROIV opened at $10.68 on Friday. The company has a market capitalization of $7.62 billion, a price-to-earnings ratio of -71.20 and a beta of 1.25. The stock has a 50 day moving average of $11.21 and a 200 day moving average of $11.59. Roivant Sciences Ltd. has a 12 month low of $9.76 and a 12 month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, equities research analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $18.08.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.